News & Updates

Statin use was not associated with improved survival outcomes in the phase III APHINITY trial investigating the addition of pertuzumab to trastuzumab and chemotherapy as adjuvant treatment for patients with early HER2-positive breast cancer (BC).

The next-generation oral full-spectrum microbiome drug EBX-102-02 appears to have an acceptable safety profile in patients with irritable bowel syndrome with constipation (IBS-C) while yielding improvements in symptom severity, abdominal pain, and stool consistency, according to the results of the phase IIa TrIuMPH* study.